Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of NY-ESO-1 targeted T cells in advanced oesophagogastric cancer
ISRCTN83343031Phase 2Completed
- Sponsor
- The Christie
- Start
- Oct 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of NY-ESO-1 targeted T cells, aldesleukin, cyclophosphamide and fludarabine in esophagogastric junction cancer, esophageal cancer and gastric cancer (GC), sponsored by The Christie. Primary endpoint: Response rate according to RECIST 1.1. Started Oct 2014; status: completed.
02
Drugs
NY-ESO-1 targeted T cellsaldesleukincyclophosphamidefludarabine
03
Conditions
esophagogastric junction canceresophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on ISRCTN83343031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83343031.